Brief: Unicycive Therapeutics Q3 EPS USD -0.13
14/11/2023 21:25
Nov 14 (Reuters) - Unicycive Therapeutics Q3 operating expenses USD 5.938 million. * Q3 net income USD -4.333 million * Q3 EPS USD -0.13 * Q3 income from operations USD -5.938 million
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss